1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Demand for Cell-based Vaccines and Therapeutics
4.2.2 Rapid Growth of Biologics and Biosimilar Industry
4.2.3 Increasing R&D and Availability of Funding for Cell Therapy Research
4.3 Market Restraints
4.3.1 High Cost of Biologics and Cell-based Therapies
4.3.2 Growth Limitations of High Density Microcarrier Cultures
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Material Type
5.1.1 Alginate-Based
5.1.2 Collagen-Based
5.1.3 Dextran-Based
5.1.4 Polystyrene-Based
5.1.5 Others
5.2 By Application
5.2.1 Cell Therapy
5.2.2 Vaccine Manufacturing
5.2.3 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Danaher Corporation
6.1.2 Eppendorf AG
6.1.3 GE Healthcare
6.1.4 Lonza Group AG
6.1.5 Merck KGaA
6.1.6 Thermo Fisher Scientific Inc.
6.1.7 Sartorius AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned
 - Danaher Corporation
- Eppendorf AG
- GE Healthcare
- Lonza Group AG
- Merck KGaA
- Thermo Fisher Scientific Inc.
- Sartorius AG